PIPE-505 is the first small molecule developed specifically for the treatment of sensorineural hearing loss…
Continue Reading-
Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis
July 7, 2020, Stockholm Gesynta Pharma AB (‘Gesynta’ or ‘The Company’) a clinical-stage company…
Continue Reading -
€1.9M EU funding takes Nelli® available for all epilepsy patients
Neuro Event Labs (NEL) will use €1.9M EU Horizon 2020 grant to become the standard…
Continue Reading -
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
On April 22, 2020, the Board of Directors of Abliva AB (publ) (“Abliva” or the…
Continue Reading -
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial
Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from…
Continue Reading -
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
Press Release 02.2020: Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis…
Continue Reading -
MSD to Acquire Themis
Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis…
Continue Reading -
NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a…
Continue Reading
